🩺 Haemophagocytic Lymphohistiocytosis (HLH) Treatment: Managing a Severe Hyperinflammatory Syndrome
HOOK
Haemophagocytic Lymphohistiocytosis (HLH) is a rare but life-threatening condition in which the immune system becomes overactive, causing excessive inflammation that can damage multiple organs. Early recognition and prompt treatment are essential to improve survival and reduce complications.
HISTORY / OVERVIEW
Hemophagocytic lymphohistiocytosis occurs when immune cells become excessively activated and release large amounts of inflammatory cytokines.
HLH is classified into:
Primary (Familial) HLH: An inherited disorder caused by genetic mutations affecting immune cell function, typically presenting in infants or children.
Secondary (Acquired) HLH: Triggered by infections, autoimmune diseases, malignancies (particularly certain lymphomas), or other medical conditions.
Treatment focuses on controlling the hyperinflammatory response while treating the underlying cause.
TREATMENT APPROACHES
Immunosuppressive and Immunomodulatory Therapy
Corticosteroids to reduce excessive inflammation
Chemotherapy-based treatment protocols in appropriate patients
Targeted immunomodulatory therapies for selected cases
Intravenous immunoglobulin (IVIG) in specific clinical situations
Treatment of Underlying Triggers
Antiviral therapy for identified viral infections when appropriate
Antibiotics or antifungal medications if bacterial or fungal infections are present
Treatment of associated autoimmune disorders
Management of underlying cancers, particularly lymphomas
Curative Therapy
For many patients with inherited HLH and some with recurrent or treatment-resistant disease:
Hematopoietic stem cell transplantation may provide long-term disease control or cure.
SUPPORTIVE CARE
Supportive management may include:
Blood and platelet transfusions when indicated
Fluid and electrolyte management
Nutritional support
Intensive care monitoring for critically ill patients
Prevention and treatment of secondary infections
Management of liver, kidney, lung, or neurological complications
BENEFITS OF EARLY TREATMENT
✔ Controls excessive immune activation before irreversible organ damage occurs✔ Improves the chances of survival and recovery✔ Addresses the underlying trigger when identified✔ Reduces the risk of multi-organ failure✔ Provides a pathway to long-term disease control or cure in eligible patients
PATIENT CARE TIPS
Seek urgent medical attention for persistent high fever, severe fatigue, enlarged liver or spleen, unexplained bruising or bleeding, or rapidly worsening illness.
Follow the treatment plan closely and attend all follow-up appointments.
Report signs of infection immediately, particularly while receiving immunosuppressive therapy.
Genetic counseling may be recommended for families affected by inherited HLH.
Long-term follow-up with hematology and immunology specialists is often required after treatment.
FUTURE DEVELOPMENTS
Current research focuses on:
Earlier diagnostic biomarkers
Precision medicine and genetic testing
Novel targeted immunotherapies
Improved stem cell transplantation strategies
Safer and more effective treatment protocols
ENGAGEMENT QUESTION
Which advancement do you think has the greatest potential to improve outcomes in HLH: earlier diagnosis, targeted immunotherapies, precision genetic testing, or advances in stem cell transplantation?